The NCT0147184 trial aims to assess the safety and efficacy of BEZ235 in combination with trastuzumab for trastuzumab-resistant HER2+ breast cancer patients, comparing it to the use of lapatinib plus capecitabine in the same patient cohort. This evidence concerns the gene ERBB2 and breast cancer.